The Role of SGLT2 Inhibitors in the Management of Diabetic Retinopathy: A Literature Review.
SGLT2 inhibitors show preclinical promise for protecting eyesight in diabetes, warranting rigorous testing alongside their proven heart and kidney benefits.
This review synthesizes emerging evidence for SGLT2 inhibitors as potential agents for diabetic retinopathy prevention, noting compelling preclinical mechanisms but acknowledging that observational clinical studies are insufficient to confirm benefit independent of glycemic control improvements. Given the established cardiac and renal benefits of SGLT2i, this potential additional indication warrants rigorous prospective evaluation.
What the study was
- Study design
- Narrative literature review
- Population
- People with diabetes mellitus and diabetic retinopathy risk
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Pharmazie
Why it surfaced
Clinically relevant SGLT2 topic (active watchlist area); provides a current state-of-evidence synthesis for a potential label extension; limited by narrative review design and inconclusive clinical evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.